Glenmede Trust’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.32M | Buy |
12,722
+7,114
| +127% | +$3.15M | 0.03% | 425 |
|
|
2026
Q1 | $2.5M | Buy |
5,608
+269
| +5% | +$125K | 0.01% | 536 |
|
|
2025
Q4 | $2.42M | Buy |
+5,339
| New | +$2.3M | 0.01% | 535 |
|
|
2025
Q1 | $2.3M | Sell |
4,735
-90
| -2% | -$41.9K | 0.01% | 530 |
|
|
2024
Q4 | $1.94M | Buy |
4,825
+732
| +18% | +$339K | 0.01% | 556 |
|
|
2024
Q3 | $1.9M | Sell |
4,093
-128,725
| -97% | -$61.8M | 0.01% | 571 |
|
|
2024
Q2 | $62.3M | Sell |
132,818
-2,263
| -2% | -$982K | 0.32% | 77 |
|
|
2024
Q1 | $56.5M | Sell |
135,081
-39,015
| -22% | -$16.5M | 0.28% | 85 |
|
|
2023
Q4 | $70.8M | Sell |
174,096
-20,297
| -10% | -$7.5M | 0.37% | 67 |
|
|
2023
Q3 | $67.6M | Sell |
194,393
-4,348
| -2% | -$1.52M | 0.39% | 63 |
|
|
2023
Q2 | $62.6M | Sell |
198,741
-106
| -0.1% | -$35.7K | 0.36% | 77 |
|
|
2023
Q1 | $62.7M | Buy |
198,847
+8,144
| +4% | +$2.44M | 0.36% | 77 |
|
|
2022
Q4 | $55.1M | Buy |
190,703
+30,980
| +19% | +$9.44M | 0.32% | 82 |
|
|
2022
Q3 | $46.2M | Buy |
159,723
+2,151
| +1% | +$619K | 0.29% | 94 |
|
|
2022
Q2 | $44.4M | Sell |
157,572
-3,403
| -2% | -$911K | 0.26% | 97 |
|
|
2022
Q1 | $42M | Buy |
160,975
+147,028
| +1,054% | +$34.9M | 0.21% | 118 |
|
|
2021
Q4 | $3.06M | Sell |
13,947
-1,345
| -9% | -$262K | 0.01% | 490 |
|
|
2021
Q3 | $2.77M | Buy |
15,292
+2,493
| +19% | +$487K | 0.01% | 485 |
|
|
2021
Q2 | $2.58M | Buy |
12,799
+6,295
| +97% | +$1.32M | 0.01% | 488 |
|
|
2021
Q1 | $1.4M | Sell |
6,504
-59,113
| -90% | -$13M | 0.01% | 607 |
|
|
2020
Q4 | $15.5M | Buy |
65,617
+61,958
| +1,693% | +$14.2M | 0.09% | 263 |
|
|
2020
Q3 | $994K | Buy |
3,659
+550
| +18% | +$152K | 0.01% | 620 |
|
|
2020
Q2 | $901K | Buy |
3,109
+594
| +24% | +$161K | 0.01% | 632 |
|
|
2020
Q1 | $550K | Hold |
2,515
| – | – | ﹤0.01% | 875 |
|
|
2019
Q4 | $550K | Sell |
2,515
-94
| -4% | -$19K | ﹤0.01% | 875 |
|
|
2019
Q3 | $441K | Buy |
2,609
+292
| +13% | +$51.7K | ﹤0.01% | 926 |
|
|
2019
Q2 | $424K | Buy |
2,317
+409
| +21% | +$71.5K | ﹤0.01% | 947 |
|
|
2019
Q1 | $350K | Sell |
1,908
-276
| -13% | -$51K | ﹤0.01% | 993 |
|
|
2018
Q4 | $361K | Buy |
2,184
+444
| +26% | +$76.9K | ﹤0.01% | 933 |
|
|
2018
Q3 | $334K | Buy |
1,740
+46
| +3% | +$8.19K | ﹤0.01% | 991 |
|
|
2018
Q2 | $288K | Sell |
1,694
-87
| -5% | -$13.5K | ﹤0.01% | 965 |
|
|
2018
Q1 | $266K | Hold |
1,781
| – | – | ﹤0.01% | 1095 |
|
|
2017
Q4 | $266K | Buy |
1,781
+27
| +2% | +$4K | ﹤0.01% | 1095 |
|
|
2017
Q3 | $265K | Buy |
1,754
+99
| +6% | +$14.9K | ﹤0.01% | 1123 |
|
|
2017
Q2 | $180K | Hold |
1,655
| – | – | ﹤0.01% | 1231 |
|
|
2017
Q1 | $180K | Buy |
1,655
+658
| +66% | +$57.9K | ﹤0.01% | 1231 |
|
|
2016
Q4 | $72K | Sell |
997
-7
| -0.7% | -$570 | ﹤0.01% | 1491 |
|
|
2016
Q3 | $87K | Buy |
1,004
+304
| +43% | +$28.7K | ﹤0.01% | 1436 |
|
|
2016
Q2 | $60K | Buy |
700
+107
| +18% | +$9.25K | ﹤0.01% | 1510 |
|
|
2016
Q1 | $46K | Sell |
593
-158
| -21% | -$14.3K | ﹤0.01% | 1550 |
|
|
2015
Q4 | $94K | Hold |
751
| – | – | ﹤0.01% | 1379 |
|
|
2015
Q3 | $77K | Buy |
751
+47
| +7% | +$6.04K | ﹤0.01% | 1448 |
|
|
2015
Q2 | $85K | Sell |
704
-25,470
| -97% | -$3.21M | ﹤0.01% | 1463 |
|
|
2015
Q1 | $3.09M | Hold |
26,174
| – | – | 0.02% | 507 |
|
|
2014
Q4 | $3.11M | Buy |
26,174
+72
| +0.3% | +$8.11K | 0.02% | 484 |
|
|
2014
Q3 | $2.93M | Sell |
26,102
-165
| -0.6% | -$15.7K | 0.03% | 477 |
|
|
2014
Q2 | $2.49M | Sell |
26,267
-60
| -0.2% | -$4.21K | 0.02% | 514 |
|
|
2014
Q1 | $1.86M | Hold |
26,327
| – | – | 0.02% | 565 |
|
|
2013
Q4 | $1.96M | Buy |
26,327
+25,423
| +2,812% | +$1.77M | 0.02% | 539 |
|
|
2013
Q3 | $67K | Buy |
904
+230
| +34% | +$18.3K | ﹤0.01% | 1508 |
|
|
2013
Q2 | $53K | Buy |
+674
| New | +$49.6K | ﹤0.01% | 1511 |
|
Other funds holding VRTX
Glenmede Trust's VRTX Position: Q2 2026 in Review
Glenmede Trust increased its Vertex Pharmaceuticals (VRTX) stake by 127% in Q2 2026, buying an estimated $3.15M and bringing the position to 12,722 shares worth $6.32M. The position accounts for 0.03% of the portfolio, ranked #425.
Glenmede Trust first reported a position in VRTX in Q2 2013 and has held it in 51 quarters since. The position peaked at $70.8M in Q4 2023. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Glenmede Trust held 12,722 shares of Vertex Pharmaceuticals worth $6.32M as of Q2 2026.
- Glenmede Trust bought 7,114 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.15M.
- Vertex Pharmaceuticals made up 0.03% of Glenmede Trust's portfolio in Q2 2026, its #425 holding.
- Glenmede Trust first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Glenmede Trust's Vertex Pharmaceuticals position peaked at $70.8M in Q4 2023.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.